Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR#BI#BIV) in health children.
An investigational tetravalent combined measles, mumps, rubella, and varicella vaccine and measles-mumps-rubella and varicella vaccines at separate injection sites given at the same visit were evaluated with respect to safety and cell-mediated and humoral immune responses at 6 weeks and 1 year after vaccination.
Varicella seroconversion rates and lymphocyte proliferation responses were 100% for both vaccine groups at 6 weeks and 1 year.
However, the antibody titer to varicella was lower in the combined vaccine group at 6 weeks, but there was no statistical difference in cell-mediated immune responses.
One-year geometric mean titers were not statistically different.
Seroconversion rates for measles, mumps, and rubella were 100% for both vaccine groups at 6 weeks and 1 year.
Long-term follow-up of these immune responses is planned.
Mots-clés Pascal : Rougeole, Virose, Infection, Vaccin associé, Toxicité, Oreillons, Souche atténuée, Réponse immune, Immunoprophylaxie, Immunogénicité, Rubéole, Varicelle, Vaccin, Prévention, Enfant, Homme, Santé publique
Mots-clés Pascal anglais : Measles, Viral disease, Infection, Mixed vaccine, Toxicity, Mumps, Attenuated strain, Immune response, Immunoprophylaxis, Immunogenicity, Rubella, Varicella, Vaccine, Prevention, Child, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0150247
Code Inist : 002B05C02B. Création : 199608.